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Summary
The highest risk for the development of type I diabetes
resides with first-degree relatives of the diabetic proband,
this risk being in the order of 2,9%, 6,6% and 4,9% for
parents, siblings and children of the proband, respectively.
The major genetic markers associated with the development
of insulin-dependent diabetes mellitus (lOOM) is the posses-
sion of the HLA alleles OR3/DR4 and more recently the
absence of aspartate in the 57th position on the f:l-chain of
the HLA DO gene (HLA DO f:l Asp 57 negative). The most
important auto-immune marker for predicting preclinical lOOM
is the presence of high titres (> 40 Juvenile Diabetes Founda-
tion units) of islet cell antibodies (ICA), while the finding of
insulin auto-antibodies (IAA) is a good predictive marker in
children < 5 years of age. The presence in a susceptible
individual of ICA plus IAA is a better predictor of impending
lOOM than the presence of either of these two markers alone.
Antibodies which precipitate an islet membrane protein (MW
641<) are highly sensitive and specific markers of preclinical
lOOM. The presence of 64K antibodies may well be the most
important predictive marker of impending lOOM in the future.
The progressive decline of the first phase of insulin secretion
in response to an intravenous glucose challenge is associated
with the onset of lOOM within 18 months. Of the immuno-
therapeutic agents at present used in clinically manifest lOOM,
azathioprine has been shown to be ineffective in increasing
the remission phase, while the value of nicotinamide is con-
troversial. At present the agents showing the most promise in
inducing and maintaining remissions are cyclosporin A or a
combination. of prednisone plus azathioprine; however, further
studies are needed. As regards the prophylaxis of lOOM, the
use of immunotherapy in minute doses during the preclinical
phase or the administration of a vaccine (derived from
attenuated autoreactive T cells) to all newborn infants com-
prise some of the strategies envisaged for use in the future.
S Atr Med J 1990; 78: 462-467.
In order to answer the questions posed in the title of this
article it is necessary critically to analyse the data available in
published reports on the following issues: (i) the value of the
markers at present available for the prediction of preclinical
type I diabetes; (it) the benefit of the immunotherapeutic
agents at present in use in patients with clinically manifest
insulin-dependent diabetes mellitus (IDDM); and (iit) the
potential role of immune modulation in the prophylaxis of
IDDM.
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Early detection of lOOM
Family studies
It is well known that the highest risk for the development of
IDDM resides with fust-degree relatives of the proband. In
this regard, Tillil and Kobberling l recently calculated by age-
corrected empirical genetic-risk estimates that the overall risks
for parents, siblings and children of the proband were 2,9%,
6,6% and 4,9% respectively. However, as only lout of every 8
patients with confirmed IDDM has a positive family history,
the need for alternative markers of impending IDDM is clear.
Genetic markers
The genetic markers in IDDM are to be found in the
histocompatibility leucocyte antigen (HLA) system that resides
on the short arm of the 6th chromosome. The genes pre-
dominantly associated with IDDM are found at the HLA DR
and DQ loci.
Influence of the DR gene
It has been shown that the presence of the alleles DR3,
DR4 or DR3/DR4 seems to be significantly associated with
the development of IDDM. In this regard, retrospective studies
have shown that for a given population ± 95% of newly
diagnosed patients with IDDM po~~essedeither DR3, DR4 or
both.2 However, since ± 40% of the non-diabetic population
possess one or more of the above alleles, and since the
incidence of IDDM is only 1 - 2% in these subjects, the
possession of the HLA DR3/DR4 alleles is associated with,
but noe the cause of, increased susceptibility to the development
of IDDM. It must be noted that protection from IDDM
seems to be associated with the absence of DR3/DR4 or the
possession of the DR2 allele. More recently, Tarn ee al. 3 in a
study of first-degree relatives of insulin-dependent diabetic
subjects (IDDS), showed that the cumulative risks of becoming
insulin-dependent by the age of 25 years were increased 24
times (16%) for siblings sharing two haplotype5 (HLA identical),
increased 2,5 times (9%) for those sharing one haplotype
(haploid identical) and zero for those who shared none (HLA
non-identical).
Influence of the DQ gene
Studies involving analysis of DNA fragments from lympho-
cytes by cDNA probes (restriction fragment length poly-
morphisms) have shown that linkage exists between the HLA
DR and DQ loci. In this context, recent data suggest that the
primary association of IDDM susceptibility may lie with the
DQ rather than the DR gene. DR4 is usually associated with
DQw3 specificity, which in turn has been subdivided into
DQw3.1 and DQw3.2 subsets. Recently it has been shown
that ID DR4-positive IDDS, the DQw3.2 (DR4-DQR4) subset
appears to be associated with IDDM susceptibility, while the
DQw3.1 (DR4-DQR5) subset is associated with non-suscepti-
bility.4.s Furthermore, amino acid sequence analysis of the f:l-
chain of the HLA DQ gene product suggested that a single
amino acid of the ,B-cllain at position 57 was uniquely important
in determining susceptibility or resistance to IDDM. An
aspartate residue at this position appears to confer resistance
to IDDM, whereas the presence of the neutral amino acids
leucine, serine and valine in the 57th position is associated
with susceptibility to IDDM.6 However, recently it has been
shown that this fmding is not applicable in all IDDM popu-
lations.7,8
Auto-inunune markers
The auto-immune markers for predicting IDDM consist of
the following humoral and cell-mediated components: islet cell
antibodies (ICA); insulin auto-antibodies (IAA); antibodies to
a human islet cell antigen of MW 64000 (64KA); and the
immune activated T lymphocyres (la T cells).
Islet-cell antibodies
The ICAs are IgG antibodies directed against an intracyto-
plasmic antigen present in all islet cell types, which has been
shown to consist of a sialoglycoconjugate.9 ICAs are detectable
in approximately 55-80% of subjects with newly diagnosed
IDDM, the prevalence profcressively declining to about 20%
I - 3 years after diagnosis. 0,11 In addition, lCAs have been
detected in 3 - 6% of first-degree relatives and in less than
0,5% of the general population. 12 After three international
workshops, it has now been possible to standardise the ICA
assay where titres are expressed in terms of Juvenile Diabetes
Foundation (JDF) units. There is general consensus that
relatives of patients with type 1 diabetes whose sera contains>
40 JDF units/ml of cytoplasmic islet cell antibodies have a
high risk of developing IDDM.13 In this context, recent data
have shown that the risk of developing IDDM in first-degree
relatives, who were followed up for 8 years, was 76% in those
with high titres (> 40 JDF units) of ICA, 3% with low ICA
titres and 0,6% in those who were ICA negative.3
Insulin auto-antibodies
Since several studies have documented the presence of lAA
in new-onset type I diabetics before insulin administration and
in the relatives of overt type I diabetics before the onset of
hyperglycaemia, it has been suggested that IAA could serve as
an immunological marker for impending IDDM. It appears
that the hi~hest prevalence of pre-clinical lAAs is found in
children,14- 6 especially those < 5 years of age,'7 while IAAs
are rarely found in adult-onset type I diabetes. 18 In a recent
follow-up study ofICA-positive non-diabetic fust-degree rela-
. tives, the relatives with bOlh ICA and lAA had more impaired
insulin responses and were more likely to progress to IDDM
compared with those possessing only one of these markers. 19
64K islet-cell antigen antibodies
In contrast to the ICAs that are directed against an intra- .
cytoplasmic antigen in the islet cells, antibodies have been
described that immunoprecipitate an islet membrane protein
having a molecular weight of 64000 (64KA).20 With respect to
prediabetes, two studies that recently followed the course of
subjects deemed 'at risk' for developing IDDM have shown
that 64KAs were present in 90% of the subjects who subse-
quently developed clinical IDDM. In these studies 64KAs
were detected from 4 to 91 months before the clinical onset of
IDDM. 2I,22 Although it was claimed that 64KA demonstrated
both high sensitivity and specificity for the beta cell, recent
evidence has shown that the 64KAs can precipitate antigens in
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both somatostatin- and glucagon-containing islet cells.
However, it appears that the 64K antigen concentration is 10
times higher in beta cells than in these non-beta-cell popula-
tions. 23. Until recently, the detection of 64KA involved a
complicated and time-consuming technique confmed to isolated
,research laboratories; however, a new simplified procedure for
detecting 64KA using Western bloning with rat islet prepara-
tions has been described.23 If, through these simplified tech-
niques, detection of the highly sensitive and specific 64KA
becomes more readily available, the presence in sera of 64KA
could well become the most important predictive marker for
impending IDDM in the future.
Immune activated T lymphocytes
Since la T cells (those expressing the DR antigen on their
surface) are found in auto-immune diseases and since IDDM
is considered to have a chronic auto-immune phase, several
studies have documented the presence of increased circulating
la T cells in patients with IDDM. Earlier studies showed the
presence of increased la T cells at the onset of clinically
manifest IDDM24,25 while, more recently, several studies have
shown the presence of these cells in normoglycaemic first-
degree relatives of type I diabenc patients, many of whom on
follow-up have developed clinical diabetes.26-28 It was thus felt
that la T cells might also represent an auto-immune marker
for impending IDDM. It has been shown that, like ICAs, the
la T cells disappear within 6 months - 1 year after clinical
diabetes onset - possibly due to a reduction of the antigen to
which these markers are directed. 24,28
Metabolic markers
Ii: has been previously documented during a study of
monozygotic twins who were initially discordant for IDDM,
that during the 'pre-diabetic' phase these twins demonstrated
progressive decline in the first-phase insulin response (sum of
1 plus 3-minute values) during an intravenous glucose tolerance
test (IVGTT).29 These fmdings were subsequently confumed
in other patients deemed 'at risk' for developing IDDM.30,31
Moreover, it was shown that 95% of subjects whose fust phase
of insulin secretion was < 25jlU/ml developed overt IDDM
within 12 months. 31 However, caution must be exercised in
interpreting these insulin responses, since it has recently been
shown that blunted insulin responses can be obtained in
'normal' non-diabetic subjects between the ages of 17 years
and 25 years,32 a fmding which could be misinterpreted as a
false-positive predictive indicator. Thus, age and pubertal
status must be carefully considered when interpreting insulin
responses to IVGTT in patients suspected of having early
abnormalities of carbohydrate metabolism.
Future studies - early detection IDDM
In any epidemiological study it is important to identify the
cohort of subjects who can be considered as 'high risk' (high
yield of positives) and those considered 'low risk' (lower yield
of positives). In this regard: (i) the 'high-risk' groups relative
to the prediabetes state include: fust-degree relatives of subjects
with type 1 diabetes, patients with auto-immune disorders (i.e.
Addison's disease, thyroiditis), gestational diabetics and clinical
prediabetics with transient or interminent hyperglycaemia;
while (ii) the 'low-risk' group involves mass screening of
general populations. One such study tested 5 000 children for
the presence of ICAs and 21 positives were obtained, several
of these children have subsequently progressed to overt
IDDM.33 It appears that the most reliable predictive marker
for screening purposes is the presence of a high titre (> 40
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Fig. 1. Methodology involved in screening for and detection of
subjects 'at risk' for impending lOOM.
JDF units) of ICAs. These individuals can then be funher
investigated by testing for lAA (fluid phase RIA method), la
T cells, insulinlC-peptide response to IVGTT and HLA typing
(DRlDQ genes) in that order (Fig. 1). Armed with the above
information a reasonably accurate 'prediction profUe' can be
constructed. Recently, a dual parameter model for predicting
the onset of type 1 diabetes has been proposed,34 consisting of
the following multiple linear regression equation derived from
data of 14 fusl-degree relatives followed to onset of IDDM:
years to diabetes = 1,5 + 0,03 (1 + 3 min IVGTT
insulin) - 0,008 (IAA) R2 = 0,79 (P < 0,0002).
Although the model appears to give a good correlation, it
must be remembered that lAAs are predominantly detected in
childL_ < 5 years and insulin responses to IVGTT are known
to be highly variable. Therefore, it might be prudent in future
studies to consider the addition to this equation of ICA and la
T-cell values in order to enhance the predictive value of such
an equation.
Immunotherapy of lOOM
Current immunotherapy
Since it became widely believed that IDDM resulted from
acute-on-cl)..ronic auro-immune destruction of the pancreatic
beta cells, a number of pilot studies have investigated the use
of immunotherapy at the onset of type I diabetes in humans.
In the early trials no apparent benefits were reported with the
use oflevamisole,35 prednisone or prednisolone,36 human leuco-
cyre interferon,37 horse antithymocyre globulin plus pred-
nisone38 and plasmapharesis.39 The later and ongoing trials at
present include the use of the following drug regimens:
azathioprine; azathioprine plus prednisone; cyclosporin A; and
nicotinamide.
Azathioprine
Azathioprine, a purine analogue with suppressive effects on
both T and B lymphocyres, has been widely used in children
suffering from auto-immune disorders. The fust randomised
controlled trial using azathioprine at the onset of IDDM
reported the development of remission in 50% of the young
adult IDDS; however, these remissions were not maintained
in the 1 - 2 years after~thioprine therapy was discontinued.4O
The initial success of this study prompted a larger randomised
double-blind placebo-eontrolled trial of azathioprine in young
adults with IDDM. At the end of 1 year, the results showed
no difference in the remission rate of the IDDS compared
with controls. It was therefore concluded that at the dosage
used, azathioprine alone did not influence the remission phase
in young adults with newly diagnosed IDDM.41
Azathioprine plus prednisone
Although it has been shown that prednisone alone36 or
azathioprine alone40,'l have limited use in IDDM therapy, a
recent smdy using a combination of azathioprine plus predni-
sone in patients with newly diagnosed IDDM showed prelimi-
nary results that were slightly more promising.42 At 1 year half
the immunosuppressed patients bur only 15% of the controls
were in good metabolic control, while 15% of the immuno-
supressed bur none of the controls were insulin independent
after 12 months.
Cyclosporin A
The most promising results with immunotherapy in IDDM
have been achieved with cyclosporin A. Several studies to date
have evaluated the use of cyclosporin A in increasing the
remission phase of recent-onset IDDM.4J-47 These studies
were randomised double-blind placebo-controlled in design
and cyclosporin therapy was commenced between 6 and 14
weeks after the diagnosis of IDDM was made. Results of these
studies showed that: (I) the highest percentage of remissions
occurred if therapy was starred within 6 weeks of the diagnosis
of IDDM; (il) remissions occurred in 25 - 68% of patients
within 2 - 9 months of starting therapy; (iiz) the relative
chance of being in non-insulin-requiring remission at 1 year
was approximately 5 times that of a placebo-treated patient;
and (iv) cessation of therapy was almost always associated with
a rerum to a state of glucose intolerance or frank IDDM
within a few months.
One of the major reservations about ~e use of cyclosporin
therapy is the presence of side-effects. The most cominon
side-effects are transient hirsutism, gingival hyperplasia and
paraesthesiae,43-46 while the most serious side-effecr, viz. the
induction of lymphoma, has only been described 'using the
high doses required for patients with auto-immune dis~ases or
those receiving an organ transplant.47 In the treatment of
recent-onset IDDM, the most serious and controversial side-
effect of cyclosporin is that of nephrotoxicity. The renal
lesions described have included reduction of glomerular futra-
tion rate,46 glomerulosclerosis44 and interstitial fibrosis with
tubular atrophy.45,46 Some authors have stated that the abnormal
renal appearance on histological examination is completely
reversible on withdrawal of cyclOSporin,4 while others claim
that the lesions are ongoing despite cessation of therapy and
lead to chronic nephropathy.48 At present, cyclosporin has
been the oDly drug shown to increase the rate and length of
the early remission phase of type I diabetes. However, the
dangers of long-term immunosuppression must be weighed
against the well-known long-term complications of type I
diabetes treated with conventional insulin therapy. Thus, at
present cyclosporin therapy for recent-onset IDDM should
only be used in controlled trials conaucted in academic insti-
tutions with the necessary clinical and laboratory expertise.
Nicotinamide
The use of nicotinamide in the early diabetic state is based
on the ability of this substance to inhibit nuclear (poly-ADP-
ribose) synthetase. In IDDM, activation of this enzyme is
triggered in response to auro-immune-induced breaks in the
DNA strands of the beta cell. The nuclear (poly-ADP ribose)
synthetase of these affected beta cells have been implicated in
DNA repair using cyrosolic nicotinamide adenine dinucleotide
(NAD) as a substrate, resulting in reduced concentrations of
intracellular NAD which, in turn, is thoufght to be the fmal
step in the destruction of the beta cell. 9-50 Thus, several
reports in animal studies have shown that nicotinamide, by
Q
SAMJ VOL 78 20 OKT 1990 465
TABLE I. FACTORS ASSOCIATED WITH A FAVOURABLE
RESPONSE TO IMMUNOSUPPRESSIVE THERAPY
withdrawn, wiU it is to be hoped have a greater chance of
facilitating insulin-independent euglycaemia. At this early
'preclinical' stage of beta-cell destruction it should be possible
to reduce drug toxicity by administration of immunotherapeutic
drugs in minute or intermittent doses. In this regard it has
been shown that spontaneous insulitis was delayed and in
some cases prevented when BB rats were treated at an early
age with imenniuenc administration of cyclosporin-A therapy.60
In addition, a viable regimen of immunotherapeutic agents
given in minuce doses during this early 'preclinical' diabetic
state may include a combinacion of the following drugs: (z)
prednisone (to block islet macrophage-secreted interleukin-I
activation of resting helper T cells); (iz) cyclosporin A (to block
la T-cell-secreted interleukin-2 recruitment of helper, cytotoxic
and suppressor T cells); and (iii) nicotinamide (to increase
intracellular NAD concentration by inhibition of nuclear
(poly-ADP-ribose) synthetase activation in susceptible beta
cells). However, it must be stressed that the administration of
immunotherapeutic agents to subjects 'at risk', bur not yet
clinically diabetic, will be associated with the moral and ethical
dilemmas of 'treating' subjects who are not yet patients. Such
controversial issues will in future undoubtedly affect all clini-
cians involved in the treatment of subjects with 'preclinical'
IDDM.
Immune modulation
Since the advent of monoclonal anci-T lymphocyce ancibodies
much has been written about their possible therapeutic use in
preventing IDDM. Seve~al studies have shown that admini-
stration of monoclonal antibodies directed against immune-
activated helper T lymphocytes (CDT/),61 cytotoxic T lym-
phocytes (CDTs)62 or both63 have prevented the onset of
insulitis and IDDM in NOD mice, a strain of animal prone to
the spontaneous development of IDDM. Can these results be
extrapolated to man? Since the immune system of the NOD
mouse and that of man is vastly different, and since monoclonal
antibody therapy has been shown to be antigenic in man, this
form of possible immune therapy for the prophylaxis of IDDM
in man must be considered speculative and of limited value at
the present time. However, the dev<:lopment of a vaccine, for
administration to all newborn infants, may well be a feasible
alternative. The basis of such a vaccine would rely on identi-
fying the autoreactive T-cell population that is cardinal in the
cell-mediated destruction of the beta cell. Once identified,
these T cells can be modified (i.e. irradiated) and then consti-
tute the basis of a vaccine consisting of modified non-reactive
T cells that will be fundamental in blocking the helper T -cell
interaction with the beta-cell antigen and consequent cytotoxic
T -cell destruction of the beta cell. Studies in this direction
have already enjoyed success in the animal models of IDDMM
At the beginning of the 20th century, who would have
believed it was possible to put a man on the moon, perform
heart transplantation or begin a human life in a test tube? For
all these events to have become a reality, enough committed
increasing the NAD content in beta cells, prevented the onset
of spontaneous diabetes mellitus in non-obese diabetic ( TOD)
mice,51 prevented the induction of diabetes by alloxan and
streptozotocin in bio-breeding (BB) rats52 and showed evidence
of inducing beta-cell regeneration in rats that were partially
depancreatised.53 As regards human studies, several groups ,
have evaluated the effect of oral nicotinamide on residual beta-
cell function in patients with recent-onset IDDM. 54- 57 These
studies have shown that nicotinamide preserved the insulin
secretory capacity in newly diagnosed patients with IDDM for
periods ranging from 3 months to 12 months. Although endo-
genous insulin secretion was retained in these patients, contro-
versy existed as to whether patients on nicotinamide required
lower insulin dosage to maintain metabolic control and whether
nicotinamide therapy induced non-insulin-requiring remissions.
It appears that these discrepant results could be explained by
variations of study methodology or design. In this regard,
future studies will need to be standardised in terms of study
protocols before any meaningful consensus is to be reached as
to the value of nicotinamide therapy in patients with recent-
onset IDDM.
Future studies with immunotherapy
Due to the varying responses obtained with immunosup-
pressive agents in recent-onset IDDM, it might be wonh
while noting the factors that have been associated with early
remission in these subjects. In this regard, the study using a
combination of prednisone and azathioprine42 noted that the
best response to immunosuppression correlated with older age,
better initial metabolic status (determined by lower HBA, and
higher stimulated C-peptide values) and post-immunosup-
pression lymphopenia «1800 lymphocytes/cm3). The French
study45 using cyclosporin A in children with recent-onset IDDM
showed that the predictive markers associated with early
remission included better metabolic control (assessed by HBA,
and stimulated C-peptide values) and the least body-weight
loss. A prospective study, which analysed the predictors of
beta-cell survival in patients with recent-onset IDDM, con-
cluded that the survival of functioning beta cells was signifi-
cantly shonened the younger the subject was at disease onset,
if. ICAs were present at diagnosis, and if the subjects were
male.5S Thus, by combining the information obtained regarding
the positive predictors associated with early remission, it may
be possible to improve remission rates by the seleceed use of
immunosuppressive therapy in subjects known to possess these
positive predictive criteria (Table I). In addition, as no study
to date has exceeded 1 year's duration, it is imponant that
further studies of immunosuppressive therapy in IDDM should
be designed to last at least 2 years before final conclusions are
drawn.
Prophylaxis of lOOM
Pre-clinical IDDM
All immunotherapy to date has been given to patients at the
time of clinically manifest IDDM, a state known to be asso-
ciated with the death of 80 - 90% of the beta-cell mass.59 Thus,
it is not surprising that, although initial remissions occurred,
once immunotherapy was withdrawn most patients rapidly
became insulin-dependent, since the remaining 10 - 20% of
beta cells were unable to maintain a state of normoglycaemia.
Thus, it may be more advantageous in future studies to
identify the subjects 'at risk' for developing IDDM (via the
aforementioned markers) and introduce immunotherapy at
this 'preclinical' stage in an attempt to salvage a larger concen-
tration of viable beta cells, which, after immunotherapy is
Clinical
Older age at onset of
lOOM (> 12 years)
Female sex
Minimal weight loss
before clinical onset of lOOM
Laboratory
HBA, < 8%
Stimulated C-peptide
> 0,6 nmolll
Lymphopenia « 1 800
lymphocytes/cm3) after
immunotherapy
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people had to wall[ them to be done and believed them
possible to do. Such will have to be the state of affairs
regarding the future prediction and prevention of type I
diabetes. However, before this can become reality, like all
other new scientific truths, a diabetic vaccine will have to pass
through the following three classic stages of recognition:
'Firstly, people would say that it conflicts with the Bible
or other established doctrines or scientific dogma; next,
they would say that it had all been discovered before;
fmally, as it became an established fact, they would say
that they had always believed it could be done.'
- Louis Agassiz, 1807-1873 - American naturalist
This work was supported by a grant from the South African
Medical Research Council.
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Malaria at Johannesburg Hospital
A retrospective study
K. T. JAIRAM, F. S. E. MONTEAGUDO, S. L. MOCH, I. HAVLlK
Summary
A total of 43 patients diagnosed as having malaria were
admitled to Johannesburg Hospital during 1988; 40 (94%)
were infected with Plasmodium falciparum. Only 26 patients
(60%) were recorded as having used prophylaxis of any kind;
chloroquine alone and in combination was used as prophy-
laxis by 17:. Patients were treated with quinine (alone or in
combination) in 67% of cases. In 42% of patients chloro-
quine-resistant malaria was considered a possibility.
S Air Med J 1990: 78: 467-469.
Patients and methods
Johannesburg Hospital has 833 beds at present and during
1988 there were approximately 32051 admissions. The hospital
serves as a teniary referral centre and is a teaching hospital of
the University of the Witwatersrand. The records of the
Haematology Laboratory of the South African Institute for
Medical Research in Johannesburg, which serves the hospital,
were studied to identify all patients with positive malaria
smears admined during 1988. The medical records of these
patients were then obtained from the Medical Records Depart-
ment.
Results
TABLE I. INCIDENCE OF MALARIA IN DIFFERENT
AGE GROUPS
There were 43 positive blood smears from 32 male and 11
female patients (median age 30 years; range 3 - 66 years). The
incidence of malaria in the different age groups is shown in
Table I.
Over the last 10 - 15 years the deterioration in the incidence of
malaria in Mrica has been partly due to the increasing spread
of a Plasmodium falciparum population that is resistant to
chloroquine and other drugs. There have been repons of
cWoroquine-resistant P. falciparum malaria from regions such
as Ethiopia,! Kenya,2 East Mrica,3 northern Malawi4 and
Mozambique5 and cWoroquine resistance has also been con-
firmed in vicro in southern Mrica.6,7
The difficulty of malaria control in cWoroquine-resistant
parasites is further compounded by the toxicity of alternative
drugs that make it difficult to propose effective and safe
medication for chemoprophylaxis and therapy.
A selected group of malaria patients and the drugs used in
their therapy is reviewed. It is imponant to note that Johan-
nesburg Hospital is a teniary referral centre and the patients
reponed may not be representative of the general population.
Age group (yrs)
0-10
11 - 20
21 - 30
31 - 40
41 - 50
51 - 60
61 - 70
No. of patients
2
5
20
7
3
4
2
%
5
12
46
16
7
9
5
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Types of malaria
Infection with P. falciparum was the most common type of
malaria seen and occurred in 40 patients (94%). Two patients
were infected with P. vivax and P. ovale, respectively, and in 1
patient the type of malaria was not identified.
